Also serving the communities of De Luz, Rainbow, Camp Pendleton, Pala and Pauma

Update on Parkinson's disease to be given

FALLBROOK – North County Parkinson's Support Group Fallbrook invites anyone interested to join their monthly support group meeting Friday, Sept. 22, 10 a.m. to noon at the Fallbrook Regional Health and Wellness Center, 1636 E. Mission Road.

The speakers will be Ed Hunter, account executive at AbbVie Neuroscience-Parkinson's and Zoltan Mari, MD (Virtual live), director for Parkinson & Movement Disorders Cleveland Clinic - Lou Ruvo Center for Brain Health, Las Vegas. Their topic is “Parkinson's Duopa Therapy & Update on PD Research.”

AbbVie was founded in 2013 when it became a separate company from Abbott. "Since the beginning, our mission hasn't wavered. Our combination of focused innovation and commercial scale brings differentiated products to market that benefit patients, customers, and health care providers.”

AbbVie is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture, and sale of a broad line of proprietary pharmaceutical products.

Duopa was approved by the FDA in 1975. Duopa is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease.

Hunter is currently serving the San Diego area and was instrumental in securing Dr. Mari as the primary speaker for this meeting. Dr. Mari will be joining the group from a remote location via a web connection.

A discussion will follow the Duopa presentation focusing on the future of Parkinson's research with the recent finding of the Parkinson biomarker. The tool, called the a-synuclein seeding amplification assay (aSyn-SAA), can detect pathology in spinal fluid not only of people diagnosed with Parkinson's, but also in individuals who have not yet been diagnosed or shown clinical symptoms of the disease, but are at high risk of developing it.

The assay can confirm the presence of abnormal alpha-synuclein, detected in most people with PD, with astonishing accuracy: 93% of people with Parkinson's who participated in the assay were proven to have abnormal alpha-synuclein.

Dr. Mari is also a Clinical Professor at UNLV, and Adjunct Associate Professor of Neurology at Johns Hopkins University. He trained many Movement Disorder fellows as fellowship director at Hopkins University. Dr. Mari is the Chairman of the Parkinson Study Group’s Motor Working Group and Associate Editor of the Parkinsonism and Related Disorders journal. He authored over 120 peer-reviewed papers, several book chapters, and patents. He was PI on dozens of pivotal PD trials, including AbbVie & LCIG trials. Dr. Mari is an avid educator, serving as activity director or co-director of over 100 CME activities.

In addition to the speaker presentation, breakout groups held for a time of sharing, coffee and refreshments will follow the program.

This meeting is held in support of persons with Parkinson's disease, care partners and people interested in improving the world of those affected by Parkinson’s disease.

For more information, call Irene, 760-731-0171 or Lorie, 760-453-3045 or email [email protected].

Submitted by the Fallbrook Parkinson's Support Group.

 

Reader Comments(0)